Compare Procter & Gamble Health with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs AJANTA PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH AJANTA PHARMA PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
 
P/E (TTM) x 18.2 24.7 73.6% View Chart
P/BV x 7.3 6.9 106.6% View Chart
Dividend Yield % 6.5 0.5 1,261.6%  

Financials

 PROCTER & GAMBLE HEALTH   AJANTA PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
AJANTA PHARMA
Mar-19
PROCTER & GAMBLE HEALTH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,5491,422 249.6%   
Low Rs1,301898 145.0%   
Sales per share (Unadj.) Rs511.4233.5 219.0%  
Earnings per share (Unadj.) Rs61.344.0 139.4%  
Cash flow per share (Unadj.) Rs74.052.2 141.9%  
Dividends per share (Unadj.) Rs440.009.00 4,888.9%  
Dividend yield (eoy) %18.10.8 2,338.0%  
Book value per share (Unadj.) Rs927.8255.1 363.7%  
Shares outstanding (eoy) m16.6088.02 18.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.75.0 95.5%   
Avg P/E ratio x39.626.4 150.0%  
P/CF ratio (eoy) x32.822.2 147.4%  
Price / Book Value ratio x2.64.5 57.5%  
Dividend payout %717.920.5 3,506.9%   
Avg Mkt Cap Rs m40,257102,081 39.4%   
No. of employees `0001.16.8 16.7%   
Total wages/salary Rs m1,3134,307 30.5%   
Avg. sales/employee Rs Th7,486.73,022.6 247.7%   
Avg. wages/employee Rs Th1,157.6633.4 182.8%   
Avg. net profit/employee Rs Th897.2569.1 157.7%   
INCOME DATA
Net Sales Rs m8,49020,554 41.3%  
Other income Rs m244211 115.7%   
Total revenues Rs m8,73420,765 42.1%   
Gross profit Rs m1,4825,664 26.2%  
Depreciation Rs m211721 29.3%   
Interest Rs m012 0.0%   
Profit before tax Rs m1,5145,143 29.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5631,273 44.2%   
Profit after tax Rs m1,0173,870 26.3%  
Gross profit margin %17.527.6 63.3%  
Effective tax rate %37.124.8 150.1%   
Net profit margin %12.018.8 63.7%  
BALANCE SHEET DATA
Current assets Rs m15,34311,812 129.9%   
Current liabilities Rs m1,9603,776 51.9%   
Net working cap to sales %157.639.1 403.2%  
Current ratio x7.83.1 250.2%  
Inventory Days Days4977 63.0%  
Debtors Days Days2882 34.9%  
Net fixed assets Rs m1,20914,398 8.4%   
Share capital Rs m166175 94.6%   
"Free" reserves Rs m15,23522,277 68.4%   
Net worth Rs m15,40122,452 68.6%   
Long term debt Rs m07 0.0%   
Total assets Rs m17,59526,962 65.3%  
Interest coverage xNM444.3-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 63.3%   
Return on assets %5.814.4 40.2%  
Return on equity %6.617.2 38.3%  
Return on capital %10.323.0 44.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63610,682 15.3%   
Fx outflow Rs m4,3682,102 207.8%   
Net fx Rs m-2,7328,580 -31.8%   
CASH FLOW
From Operations Rs m-1,3043,748 -34.8%  
From Investments Rs m12,697-2,228 -569.9%  
From Financial Activity Rs m-301-1,475 20.4%  
Net Cashflow Rs m11,09345 24,541.8%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 1.6 1,174.2%  
FIIs % 1.0 7.6 13.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.0 171.2%  
Shareholders   28,591 20,968 136.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Factors Behind the Sensex Rally, Easy Trip Planners IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended their day on a strong note yesterday. Benchmark indices rallied for the third consecutive day in a row with the BSE Sensex trading above 51,000-mark again

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Mar 3, 2021 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS